Syndax Pharmaceuticals, Inc. Prepaid Expense and Other Assets, Current
Syndax Pharmaceuticals, Inc. (SNDX) had Prepaid Expense and Other Assets, Current of $17.48 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes
us-gaap:PrepaidExpenseAndOtherAssetsCurrent · last filed 2026-08-04
- 2026-06-30: Prepaid Expense and Other Assets, Current $17.48M.
- 2026-03-31: Prepaid Expense and Other Assets, Current $16.10M.
- 2025-12-31: Prepaid Expense and Other Assets, Current $13.50M.
- 2025-09-30: Prepaid Expense and Other Assets, Current $9.52M.
| Period end | Prepaid Expense and Other Assets, Current | Prepaid Expense and Other Assets, Current as first filed |
|---|---|---|
| 2026-06-30 | $17.48M 10-Q · filed 2026-08-04 | |
| 2026-03-31 | $16.10M 10-Q · filed 2026-04-30 | |
| 2025-12-31 | $13.50M 10-Q · filed 2026-08-04 | |
| 2025-09-30 | $9.52M 10-Q · filed 2025-11-03 | |
| 2025-06-30 | $9.88M 10-Q · filed 2025-08-04 | |
| 2025-03-31 | $8.46M 10-Q · filed 2025-05-05 | |
| 2024-12-31 | $8.54M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $4.91M 10-Q · filed 2024-11-05 | |
| 2024-06-30 | $4.21M 10-Q · filed 2024-08-01 | |
| 2024-03-31 | $4.67M 10-Q · filed 2024-05-08 | |
| 2023-12-31 | $3.29M 10-K · filed 2025-03-03 | |
| 2023-09-30 | $3.75M 10-Q · filed 2023-11-02 | |
| 2023-06-30 | $3.06M 10-Q · filed 2023-08-03 | |
| 2023-03-31 | $1.91M 10-Q · filed 2023-05-08 | |
| 2022-12-31 | $1.92M 10-K · filed 2024-02-27 | |
| 2022-09-30 | $2.27M 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $2.39M 10-Q · filed 2022-08-08 | |
| 2022-03-31 | $9.03M 10-Q · filed 2022-05-09 | |
| 2021-12-31 | $1.45M 10-K · filed 2023-02-28 | $8.35M 10-K · filed 2022-03-01 |
| 2021-09-30 | $8.42M 10-Q · filed 2021-11-15 | |
| 2021-06-30 | $9.31M 10-Q · filed 2021-08-09 | |
| 2021-03-31 | $7.61M 10-Q · filed 2021-05-11 | |
| 2020-12-31 | $5.68M 10-K · filed 2022-03-01 | |
| 2020-09-30 | $7.16M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $4.94M 10-Q · filed 2020-08-06 | |
| 2020-03-31 | $5.09M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $2.56M 10-K · filed 2021-03-12 | |
| 2019-09-30 | $2.51M 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $5.15M 10-Q · filed 2019-08-07 | |
| 2019-03-31 | $4.79M 10-Q · filed 2019-05-08 | |
| 2018-12-31 | $2.33M 10-K · filed 2020-03-05 | |
| 2018-09-30 | $6.15M 10-Q · filed 2018-11-05 | |
| 2018-06-30 | $6.21M 10-Q · filed 2018-08-08 | |
| 2018-03-31 | $5.98M 10-Q · filed 2018-05-09 | |
| 2017-12-31 | $3.36M 10-K · filed 2019-03-07 | |
| 2017-09-30 | $3.28M 10-Q · filed 2017-11-08 | |
| 2017-06-30 | $4.11M 10-Q · filed 2017-08-10 | |
| 2017-03-31 | $4.17M 10-Q · filed 2017-05-09 | |
| 2016-12-31 | $3.03M 10-K · filed 2018-03-08 | |
| 2016-09-30 | $1.55M 10-Q · filed 2016-11-14 | |
| 2016-06-30 | $1.87M 10-Q · filed 2016-08-15 | |
| 2016-03-31 | $2.04M 10-Q · filed 2016-05-16 | |
| 2015-12-31 | $1.46M 10-K · filed 2017-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |